Cidara Therapeutics, Inc.
CDTX
Rankning i aktier
#3181
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Aktiekurs
$221.38
Senast synkroniserad: 2026-01-08
Marknadsvärde
$5.61B
Förändring (1 dag)
0.00%
Förändring (1 år)
118.07%
Land
US
Handel Cidara Therapeutics, Inc. (CDTX)
Kategori
Healthcare
EPS för Cidara Therapeutics, Inc. (CDTX)
EPS per September 2025 TTM: $-11.78
Enligt Cidara Therapeutics, Inc.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $-11.78. Vid slutet av 2023 hade bolaget ett EPS på $-5.25, en minskning jämfört med EPS från 2022 som var $-9.61.
EPS-historik för Cidara Therapeutics, Inc. från 2012 till 2026
EPS vid slutet av varje år
| År | EPS | Ändra |
|---|---|---|
| 2026 (TTM) | $-11.78 | -55.96% |
| 2024 | $-26.75 | 409.52% |
| 2023 | $-5.25 | -45.37% |
| 2022 | $-9.61 | -40.68% |
| 2021 | $-16.20 | -55.04% |
| 2020 | $-36.03 | 34.54% |
| 2019 | $-26.78 | -41.30% |
| 2018 | $-45.62 | -28.37% |
| 2017 | $-63.69 | -4.21% |
| 2016 | $-66.49 | 42.19% |
| 2015 | $-46.76 | -83.88% |
| 2014 | $-290.15 | 249.41% |
| 2013 | $-83.04 | 85.77% |
| 2012 | $-44.70 | 0.00% |
EPS för liknande företag eller konkurrenter
| Företag | EPS | EPS-differens | Land |
|---|---|---|---|
| $17.32 | -247.03% |
US
|
|
| $-7.98 | -32.26% |
US
|
|
| $-5.29 | -55.09% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -335.48% |
NL
|
